Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine

B. L. Slomiany, E. Piotrowski, J. Piotrowski, K. A. Zirvi, Y. H. Liau, V. L.N. Murty, A. Slomiany

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


1. Rat gastric mucosal cells, subjected to phospholipid labeling by incubating the cell suspension in DMEM with [3H]choline, were exposed to different concentrations (0-150 μM) of H2-receptor antagonists, ebrotidine and ranitidine, and the phospholipid secretory responses were evaluated. 2. In the absence of the drugs, the secretion of choline-containing phospholipids over a 1 hr period averaged 3.97% of the total cellular labeled phospholipids. Ebrotidine caused a dose-dependent increase in the rate of phospholipid secretion which was most pronounced at 1 hr and persisted for at least 2 hr. The maximal effect was attained at 120 μM ebrotidine giving a 36% increase in phospholipid secretion. 3. The phospholipid secretory response to ebrotidine was accompanied by an increase in gastric mucosal cell cAMP level which reached a maximum value of 2.1-fold over that of controls at 1 hr. Ranitidine, in contrast, neither evoked increase in cAMP level nor caused any stimulation in phospholipid secretion. 4. The results indicate that the gastroprotective properties of ebrotidine are associated with the ability of the drug to elicit a rapid stimulation in gastric mucus phospholipid secretion, and that ranitidine does not possess such property.

Original languageEnglish (US)
Pages (from-to)1033-1037
Number of pages5
JournalGeneral Pharmacology
Issue number5
StatePublished - Sep 1994

All Science Journal Classification (ASJC) codes

  • Pharmacology


  • Gastric mucus phospholipid
  • ebrotidine
  • ranitidine


Dive into the research topics of 'Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine'. Together they form a unique fingerprint.

Cite this